非酒精性脂肪性肝病与酒精性肝病2016年研究进展

Research advances in nonalcoholic fatty liver disease and alcoholic liver disease in 2016

非酒精性脂肪性肝病已经成为世界第一大肝脏疾病，仍然有继续增加的趋势，但迄今没有理想的有效治疗药物。非酒精性脂肪性肝病病理生理学的多个效应／介质之间的复杂和动态的相互作用带来了新的见解，有助于分层和重新定义临床表型、评估疾病的易感性和进展的多重性，也可能为今后的治疗提供新的靶点。因此，非酒精性脂肪性肝病病理生理学的研究势在必行。酒精性肝病严重危害健康，是导致终末期肝病的重要原因。流行病学、发病机制、诊治方法、转归预后等4个方面的研究均取得一定进展，现作一简要概述。

Nonalcoholic fatty liver disease （NAFLD） has become the most important liver disease in the world and its prevalence rate still tends to increase. However, there are still no effective drugs so far. The complex and dynamic interactions between multiple effects/mediators in the pathophysiology of NAFLD provide new insights and help with stratification and ~definition of clinical phenotypes and evaluation of disease susceptibility and multiplicity of progression. They may also provide new targets for future Irealment. Therefore, research on the pathophysiology of NAFLD is imperative. Alcoholic liver disease is a great harm to health and an important cause of end-stage liver disease. Some progress has been made in the research on alcoholic fiver disease around the world in 2016. This article reviews the research advances in alcoholic liver disease in 2016 from the aspects of epidemiology, pathogenesis, diagnostic and therapeutic methods, and prognosis.